TABLE 2.

Percent of the P_exsC promoter probe shifted by wild-type ExsA and the indicated mutants in the presence of the N-hydroxybenzimidazoles

ExsA	% of probe shifted in the presence of the indicated N-hydroxybenzimidazolea
	4816	5330	5631	5707	5784	5816
Wild type	34 ± 4	60 ± 4	8 ± 5	3 ± 2	7 ± 4	7 ± 5
H180E mutant	45 ± 4	50 ± 5	11 ± 1	4 ± 1	9 ± 4	32 ± 5*
N183E mutant	40 ± 2	59 ± 3	15 ± 2	51 ± 6*	45 ± 8*	41 ± 4*
I217E mutant	26 ± 9	71 ± 10	2 ± 1	35 ± 4*	69 ± 1*	2 ± 1
E184A mutant	3 ± 1*	59 ± 6	7 ± 1	33 ± 4*	28 ± 4*	5 ± 4
K186A mutant	55 ± 5	76 ± 2	15 ± 3	30 ± 7*	16 ± 3	42 ± 3*
P213A mutant	13 ± 6	59 ± 6	3 ± 1	2 ± 1	2 ± 1	3 ± 1
R214A mutant	2 ± 1*	39 ± 1	2 ± 1	3 ± 1	38 ± 1*	2 ± 1
M241A mutant	63 ± 6*	51 ± 10	2 ± 1	6 ± 4	71 ± 4*	63 ± 11*
S246A mutant	28 ± 4	72 ± 9	2 ± 1	13 ± 5*	25 ± 7	29 ± 5*

^aThe N-hydroxybenzimidazoles were used at a concentration of 125 μM. Each horizontal data set represents the percent of the P_exsC promoter probe shifted following treatment with each N-hydroxybenzimidazole relative to an untreated control normalized to 100%. *, P < 0.01.